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Abstract
Background: The clinical utility for mefloquine has been eroded due to its association with adverse neurological
effects. Better-tolerated alternatives are required. The objective of the present study was the identification of lead
compounds that are as effective as mefloquine, but exhibit physiochemical properties likely to render them less
susceptible to passage across the blood-brain barrier.
Methods: A library of drug-like non-piperidine analogs of mefloquine was synthesized. These compounds are
diverse in structure and physiochemical properties. They were screened in appropriate in vitro assays and
evaluated in terms of their potential as lead compounds. The correlation of specific structural attributes and
physiochemical properties with activity was assessed.
Results: The most potent analogs were low molecular weight unconjugated secondary amines with no
heteroatoms in their side-chains. However, these compounds were more metabolically labile and permeable than
mefloquine. In terms of physiochemical properties, lower polar surface area, lower molecular weight, more freely
rotatable bonds and fewer H-bond acceptors were associated with greater potency. There was no such
relationship between activity and LogP, LogD or the number of hydrogen bond donors (HBDs). The addition of an
H-bond donor to the side-chain yielded a series of active diamines, which were as metabolically stable as
mefloquine but showed reduced permeability.
Conclusions: A drug-like library of non-piperidine analogs of mefloquine was synthesized. From amongst this
library an active lead series of less permeable, but metabolically stable, diamines was identified.
Background
Traditionally anti-malarial drugs have been used for
prophylaxis and/or treatment. The target product pro-
files for these indications are very different and develop-
ing drugs simultaneously for both indications has
become more difficult in recent times [1]. A new
approach, intermittent preventive treatment (IPT) is the
prevention of morbidity or mortality due to malaria
through the intermittent administration of a single dose
treatment of a drug at full therapeutic doses to asympto-
matic, otherwise healthy infants (IPTi), pregnant women
(IPTp) and travelers (IPTt) [1-3]. Drugs for these indica-
tions can theoretically be used for malaria prophylaxis
as well. Drugs for IPTx indications and prophylaxis
should ideally exhibit a long half-life, be very well-toler-
ated and safe in pregnancy. Mefloquine exhibits two of
these characteristics, but will likely not find use as an
IPT drug because of the adverse CNS events observed
at the treatment level doses [4] that may be required for
IPT. However, this would presumably not be an issue
for next generation analogs of mefloquine without such
a liability.
The minimum target product profile for such com-
pounds would be similar clinical effectiveness to meflo-
quine, a long half-life, and fewer adverse neurological
events. In the context of a drug discovery program this
translates to useful potency against mefloquine-resistant
strains of Plasmodium falciparum, adequate metabolic
stability, long half-lives in vivo,a n ds u p e r i o r
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effects. Since mefloquine accumulates in the central ner-
vous system and has multiple CNS targets (see discus-
sion in our earlier papers [5,6]), it is logical to reduce
partitioning of mefloquine into the CNS rather than
focus on a specific neurological target. It is well known
that lower permeability through the blood-brain barrier
can be engineered into a chemical scaffold through
manipulation of such properties as lipophilicity, hydro-
gen bonds, polar surface area, molecular weight, acidity
and molecular flexibility [7-10]. Ideally, such a next gen-
eration quinoline methano lw o u l db em o r ep o t e n t
against mefloquine-resistant strains of P. falciparum in
vitro than mefloquine and lack cross-susceptibility to
mefloquine. However, since mefloquine is used effec-
tively in combination with other drugs [11], which
would likely also be the case for a next generation qui-
noline methanol, these traits are not requirements for
the target product profile.
Previously, it was reported that opening of the piperi-
dine ring at the 4-position of the quinoline scaffold is
associated with improved potency and selectivity relative
to mefloquine [12]. However, the Walter Reed Army
Institute of Research archive contains relatively few ana-
logs of this type associated with the 2,8-trifluoromethyl
quinoline core. This scaffold, therefore, represented a
logical starting point from which to synthesize a new
library of 4-position next generation quinoline metha-
nols [13]. Structure-activity relationships amongst
selected compounds from this library were recently
reported [13]. The present study describes the most
active compounds from this library together with the
physiochemical properties that characterize them. The
data suggest that diamine quinoline methanols exhibit
the physiochemical properties required to achieve a bal-
ance between potency, reduced blood-brain barrier
penetration, and metabolic stability.
Methods
Library synthesis and physiochemical properties
A library of one hundred ninety eight next generation
quinoline methanols was synthesized. All analogs were
modified at the 4-position. The synthesis was designed
to provide rapid access to a broad range of chemotypes
at the 4-position in a single step from the 4-(oxiran-2-
yl)-2,8-bis(trifluoromethyl)quinoline scaffold using the
general reaction scheme outlined in Figure 1.
Compounds were designed to be rule of 5 (RO5) com-
pliant [14] and to encompass the widest feasible range
of molecular weight (MW), LogD, LogP, freely rotatable
bonds (FRBs), polar surface area (PSA), hydrogen bond
donors (HBDs) and hydrogen bond acceptors (HBAs,
see Table 1). All physiochemical properties were calcu-
lated using ACD (Version 10, ACD Labs, Toronto,
Canada) except LogD (pH 7.4) which was determined
using Pipeline Pilot. (Version 6.1, Accelrys, San Diego,
California). These properties have been defined in detail
elsewhere [15]. They numerically represent the size
(MW), lipophilicity (LogD and LogP), molecular flexibil-
ity (FRBs) and H-bonding capacity (HBDs and HBAs) of
a compound, all of which impact biological properties
important in drug development.
A R05 compliant compound was looked for, since
molecules of this type are more likely to be orally bioa-
vailable [14]. An R05 compliant compound is one that
possesses at least three of the following properties;
molecular weight < 500, LogP is < 5, HBDs < 5 and
HBAs < 10. These breakpoints make sense given that
good oral bioavailability is a function of solubility and
permeability. Larger compounds (high MW) tend to be
less permeable and less soluble. Greater lipophilicity
(LogP) may improve permeability, however too much
lipophilicity may reduce aqueous solubility. Compounds
with more H-bonds (higher HBD and HBA counts) tend
to have greater solubility, but this may come at the
expense of lower permeability.
Limiting the physiochemical properties of a molecule to
R05 space may have unintended effects on other para-
meters of interest. For examp l e ,aq u i n o l i n em e t h a n o l
could theoretically require a number of H-bonds in excess
of R05 constraints if blood-brain barrier permeability is to
be limited, but might be poorly bioavailable and lack anti-
malarial activity if permeability across the intestine wall
and parasite membranes is similarly curtailed. There may
also be unintended pharmacokinetic consequences if
greater polarity was associated with greater renal clear-
ance. Therefore, the construction of a library with the
maximum diversity of physiochemical properties should
maximize the likelihood of identifying a lead series with
the appropriate balance of biological properties.
Plasmodium falciparum susceptibility assays
The in vitro activities of quinoline methanols against P.
falciparum strains W2, D6, TM91C235, and TM90C2A
were evaluated using the traditional labeled hypox-
anthine assay of Desjardins et al [16] as modified by
Milhous et al [17]. These four P. falciparum strains
were selected since they have various levels of resistance
to conventional anti-malarials. W2 is chloroquine resis-
tant and mefloquine sensitive, D6 is chloroquine sensi-
tive but naturally less susceptible to mefloquine,
TM91C235 is resistant to mefloquine, chloroquine, and
pyrimethamine as is TM90C2A, however this latter
parasite is a two pfmdr1 copy strain (pfmdr1 amplifica-
tion has been associated with clinical mefloquine resis-
tance). Mefloquine is routinely screened in these assays
to ensure the validity. Historical values for mefloquine
against all the strains are reported in Table 1.
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Page 2 of 10Toxicity assays
General cytotoxicity was assessed by first determining
LC50 ’s against a rodent macrophage (RAW) cell line
using the 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay as described in one of our
earlier studies [5]. This screen was conducted to identify
compounds that may require de-selection due to gener-
alized toxicity. Mefloquine is routinely screened in this
assay to ensure validity. Historical data for mefloquine is
reported in Table 2. While the central nervous system
targets of mefloquine are not known, direct neurocyto-
toxicity at high concentrations, as well as modulation of
adenosine receptors, may play a role [18,19]. Selection
of compounds with more favorable profiles than meflo-
quine against these targets may be advantageous, all
other factors being equal. In vitro neurocytotoxicity was
assessed by determining LC50s against primary mouse
neurons using the MTT assay as described previously
[5]. Inhibition of the A2A and A1 receptors was deter-
mined at 200 nM in duplicate by Caliper Biosciences
(Hanover, Maryland).
Permeability assay
Since mefloquine has multiple potential targets and the
clinically relevant ones are not known, reduced blood-
brain barrier penetration is a logical approach to reduce
exposure of multiple targets to a next generation quino-
line methanol. For this reason, the apparent permeability
of selected compounds across MDR1-transfected MDCK
cell monolayers [20] was determined. This assay is an in
vitro surrogate of the blood-brain barrier.
Permeability was determined by Absorption Systems
(Exton, PA). MDR1-MDCK cell monolayers were grown
to confluence on collagen-coated, microporous, polycar-
bonate membranes in 12-well Costar Transwell plates.
Data are considered valid for a specific assay plate if
TEER values are < 1400 Ω cm
2,t h eP app of propanolol
is between 10-30 × 10
-6 cm/s and the Papp of atenolol is
<0 . 5×1 0
-6 cm/s. The permeability assay buffer was
Hanks Balanced Salt Solution containing 10 mM HEPES
and 15 mM glucose at a pH of 7.4. A known p-glyco-
protein inhibitor cyclosporin A (CSA) was also added to
the assay buffer at 10 μM. Bovine serum albumin (1%)
was added to the receiver well. The dosing solution con-
centrations of the test compounds were 5.0 μMi nt h e
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Figure 1 Structure of mefloquine and synthesis of 4-position library. The structure of mefloquine is indicated (1). The intermediate scaffold
4-(oxiran-2-yl)-2,8-bis(trifluoromethyl)quinoline (3) was synthesized from bis(trifluoromethyl)quinolin-4-ol (2) by the addition of POBr3, at 75°C -
150°C for 2 h with 91% yield. The resulting 4-bromo-2,8-bis(trifluoromethyl) quinoline was dissolved in tetrahydrofuran, cooled to -78°C and
subjected to n-butyllithium. N,N-dimethylformamide was subsequently added to afford 2,8-bis(trifluoromethyl)quinoline-4-carbaldehyde.
Utilization of Corey’s dimethylsulfonium methylide provided racemic epoxide (3). The epoxide (3) can also be purchased commercially from
Bioblocks (San Diego, California). The quinoline scaffold (3) was diversified at the 4-position in a single step with commercially available
nucleophiles.
Table 1 Physiochemical properties of the 4-position
library
Parameter* Range
MW 335-552
LogD -1.2-6.9
PSA 36-111
LogP -2.2-7.1
FRBs 3-12
HBDs 1-5
HBAs 3-8
LVs 0-1
* MW is molecular weight, PSA = polar surface area, FRBs = freely rotatable
bonds, HBDs = H-bond donors, HBAs = H bond acceptors and LVs = Lipinski
violations.
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for 30 minutes with assay buffer. After 30 minutes, the
buffer was removed, replaced with fresh buffer, and time
was recorded as 0. The addition of BSA, pre-incubation,
and use of a longer incubation time were employed to
mitigate potential low recovery or permeability that is
sometimes observed for lipophilic or ‘sticky’ compounds.
Cell monolayers were dosed on the apical side (A-to-B)
or basolateral side (B-to-A) and incubated at 37°C with
5% CO2 in a humidified incubator. After 2 hours, ali-
quots were taken from the receiver chambers. Samples
were taken from the donor chamber at 0 and 2 hours.
Each determination was performed in duplicate. The
lucifer yellow flux was also measured for each mono-
layer to ensure no damage was inflicted to the cell
monolayers during the flux period. All samples were
assayed by LC/MS/MS using electrospray ionization.
Apparent permeability in the apical (A-B direction),
PappA-B, and percent recovery are reported. Apparent
permeability is a measure of the rate of transport across
the cell monolayer. Percent recovery refers to the
amount of compound recoverable at the end of the
assay. Low recovery may indicate non-specific binding
to assay plates, instability or accumulation in the cell
pellet. In the case of mefloquine, relatively low recovery
is likely a consequence of accumulation in cell mem-
branes [21,22] rather than non-specific binding.
The apparent permeability, Papp, and percent recovery
were calculated as follows:
Papp = (dCr/dt) × Vr/(A × C0) (1)
Percent Recovery = 100 × ((Vr × Cr
final)+( V d×
Cd
final))/(Vd × CN) (2)
where,
dCr/dt is the slope of the cumulative concentration in
the receiver compartment versus time in μMs
-1.
Vr is the volume of the receiver compartment in cm
3.
Vd is the volume of the donor compartment in cm
3.
A is the area of the cell monolayer (1.13 cm
2 for 12-
well Transwell).
C0 is the measured concentration of the donor cham-
ber at time 0 in μM.
CN is the nominal concentration of the dosing solu-
tion in μM.
Cr
final is the cumulative receiver concentration in μM
at the end of the incubation period.
Cd
final is the concentration of the donor in μMa tt h e
end of the incubation period.
Metabolic stability and drug-drug interaction assays
Interesting compounds were also submitted for drug-
drug interaction and metabolic stability assays. Low
IC50s against specific cytochrome P450 isoforms may
indicate the potential for a harmful drug interaction to
occur in vivo with substrates of that isoform. A lack of
metabolic stability in vitro may indicate potential meta-
bolic instability in vivo, and, therefore, a shorter half-life.
Drug interaction potential was evaluated in vitro using
BD Gentest (Franklin Lakes, NJ) CYP450 inhibition kits
as recommended by the manufacturer. Metabolic stabi-
lity assessments were conducted using in vitro liver
microsomes. Compound stocks at 10 or 20 mM
(depending on solubility) in DMSO are diluted to a final
concentration of 1 μM into a mixture containing, 0.5
mg/mL of pre-warmed pooled human or mouse liver
microsomes (BD Gentest), 1.3 mM NADP (Sigma), 3.3
mM MgCl2 (Sigma), and 0.1 M pH 7.4 PBS using a
TECAN Genesis robotic liquid handler. The reaction is
Table 2 Anti-malarial and toxicity data for compounds selected for secondary in vitro screening.*
WR# IC90 Pf (ng/ml)* LC50
RAW (μM)
**
LC50 neurons
(μM)
% A2A inhibition at
200 nM
% A1 inhibition at
200 nM
W2 D6 C235 C2A
MQ 6.2 +/- 2.8
(532)
17 +/- 11
(536)
52 +/- 30
(367)
74 +/- 32
(77)
9.0 +/- 3.7
(27)
41 62 4.0
308245 17 45 58 80 40 > 120 0 0
308255 3.8 15 19 37 58 > 120 NT NT
308257 4.7 23 23 39 14 > 120 17 79
308266 6.1 25 24 52 13 59 NT NT
308278 9.7 36 39 54 21 > 120 1 9.4
308396 6.2 29 40 48 18 52 0 2.9
308446 < 1 14 19 16 8.9 48 NT NT
398387 1.2 7 12 11 21 > 120 NT NT
308388 1.1 6.7 11 10 16 56 NT NT
308413 1.1 12 15 7.5 8.5 > 120 NT NT
* For mefloquine IC90s are presented as mean +/- standard deviation (n). ** RAW refers to the murine RAW macrophage cell line. For mefloquine LC50 is
presented as mean +/- standard deviation (n).
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phate dehydrogenase G6PD. The mixture is incubated
on a shaking platform at 37°C, and aliquots are taken
and quenched with the addition of an equal volume of
cold acetonitrile at 0, 10, 20, 30, and 60 min. Samples
are centrifuged at 3700 rpm for 10dd min at 20°C to
remove debris. Sample quantification is carried out by
LC/MS, and metabolic half-life is calculated by log plots
of the total ion chromatograph area remaining.
Results
Synthesis and primary screening
One hundred ninety eight quinoline methanols were
synthesized. The ranges of physiochemical properties
represented by the library are outlined in Table 1. The
primary screening data and physiochemical properties of
all compounds are presented in Additional File 1. Of the
original 198 compounds, 24 (12%) exhibited IC90s less
than 250 nM against mefloquine-resistant PfC2A and
cytotoxicity similar or better than mefloquine. The
structures of these compounds and their IC90s are pre-
sented in Figure 2. Ten of these compounds were
selected for screening in various secondary assays based
on their chemical structures. WR308278 and WR308396
were selected as they were the only compounds contain-
ing heteroatoms in the side-chain that were more potent
than mefloquine. WR308245, WR308255, WR308257
and WR308266 were selected because they were
approximately equivalent or superior to mefloquine in
terms of potency, but contained less steric bulk in their
side-chains. WR308387, WR308388, WR308413 and
WR308446 were selected as they were substantially
more potent than mefloquine in vitro.
Secondary screening
The rank-order of mefloquine and quinoline methanols
in terms of potency against the four strains of Pf was
similar in most cases (Table 2). Most of the compounds
screened were more metabolically labile than mefloquine
(Table 3). The exceptions were those in which the side-
chain was presumably less susceptible to N-dealkylation
(WR308245 and WR308257) and the diamine
WR308396. All compounds except WR308245 and
WR308255 exhibited more potent inhibitory effects on
cP450 2D6 than the other isoforms (Table 3). All the
compounds were less neurotoxic than mefloquine.
WR308245, WR308257, WR308278 and WR308387
were more permeable across MDCK-MDR1 cell mono-
layers than mefloquine (Tables 2 and 3). WR308396
exhibited slightly lower permeability than mefloquine
and half the permeability of WR308387 (Table 3). The
inhibition of the A2A and A1 receptors by four of the
analogs at 200 nM was evaluated (Table 2). In most
cases the level of inhibition observed was lower or
comparable to that observed with mefloquine. The
exception was WR308245 against the A1 receptor
(Table 2).
On the basis of its equivalent potency and metabolic
stability to mefloquine, and lower permeability, toxicity
and inhibition A2A and A1 receptors, WR308396
appeared to be the most promising compound. Accord-
ingly, a number of analogs of this lead structure were
synthesized. These compounds were all active and
exhibited improved metabolic stability and permeability
relative to mefloquine (Figure 3). In some instances,
cross-susceptibility profiles were different from
mefloquine.
Relationship between activity and physiochemical
properties
Physiochemical properties amongst inactive compounds,
active compounds with IC90s < 540 ng/ml or 1000 nM
and active compounds with IC90s < 250 nM were com-
pared. The threshold for inactivity was set at an IC90 >
540 ng/ml (or the approximate corresponding concen-
tration of 1000 nM) since this was the highest concen-
tration tested in the assay. There were no significant
differences amongst these groups in terms of LogD,
HBDs and LogP (Table 4). The most potent compounds
exhibited significantly lower molecular weights, lower
PSA and fewer HBAs compared to inactive compounds
and fewer HBAs and lower molecular weights compared
to compounds with active compounds. Active com-
pounds exhibited significantly increased FRBs relative to
inactive compounds (Table 4).
Structural characteristics of active and inactive
compounds
Analogs were categorized based upon their structural
motifs. The proportion of active (IC90 < 500 ng/ml or
1000 nM) and inactive compounds containing these
functional groups was determined and differences
between the groups were tested for significance using
Fisher’s Exact test (Table 5). The inactive group con-
tained a greater proportion of compounds in which the
4-position amino side-chain contained additional het-
eroatoms, analogs in which the hydroxyl group or amine
functionality were replaced, and compounds in which
the first nitrogen atom in the side-chain was conjugated.
The active groups of compounds contained a higher
proportion of secondary amines and compounds in
which the amino side-chain contained no additional het-
eroatoms. The inactive and active groups contained
similar proportions of tertiary and benzyl amines.
Discussion
In a previous study it was shown that non-piperidine
analogs of mefloquine such as WR177000 were more
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Figure 2 Structures and IC90s of the most potent quinoline methanols. IC90s are against the mefloquine resistant Pf C2A strain.
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Page 6 of 10Table 3 Metabolic stability, drug-drug interaction and permeability screening results for mefloquine and interesting
next generation quinoline methanols
WR# Half-life in mouse micro
(min)
IC50 1A2
(uM)
IC50 2C9
(uM)
IC50 2C19
(uM)
IC50 2D6
(uM)
IC50 3A4
(uM)
PappA-B MDCK-MDR1 in cells(%
recovery)*
MQ > 60 > 40 14 18 5.1 19 9.4 (< 40)**
308245 > 60 1.8 > 40 33 7.4 26 24 (59)
308255 25 1.5 25 25 2.9 18 NT
308257 > 60 3.9 37 26 1.9 > 40 25 (69)
308266 22 2.4 12 7.6 1.4 5.7 NT
308278 10 3.5 6.3 3.6 1.4 16 38 (54)
308396 > 60 5.4 14 5.8 0.7 3.3 8.4 (18)
308446 13 > 40 16 14 9.1 > 40 NT
398387 20 2.1 11 7 2 > 40 18 (42)
308388 16 1.2 13 3.4 0.8 33 NT
308413 19 26 19 5.8 1 > 40 NT
* Apparent permeability (PappA-B) across MDR1-transfected MDCK cell monolayers in the apical (A-B) direction. Units are 10
-6 cm/s. % recovery is presented in
brackets. ** Value for mefloquine is an average of n = 3 assays.
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MEFLOQUINE
LogD = 3.1
HBDs= 2
Pf W2 IC90 = 6.2 +/- 2.8 ng/ml
Pf D6 IC90 = 17 +/- 11 ng/ml
PF C235 IC90 = 52 +/- 30 ng/ml
Pf C2A = 74 +/- 32 ng/ml
LC50 = 3721 +/- 1514 ng/ml
HL in Microsomes > 60 min
P a p p / R e c o v e r y=9 . 4( <4 0 )
WR177000
LogD = 2.8
HBDs= 2
Pf W2 IC90 =1.7 ng/ml
Pf D6 IC90 = 6.7 ng/ml
PF C235 IC90 = 8.9 ng/ml
Pf C2A= 12.3 ng/ml
LC50 = 2780 ng/ml
HL in Microsomes = 37 min
Papp/Recovery =25.4 (58)
WR308396
LogD = 3.3
HBDs= 3
Pf W2 IC90 =6.2 ng/ml
Pf D6 IC90 = 30 ng/ml
PF C235 IC90 = 40 ng/ml
Pf C2A = 48 ng/ml
LC50 = 8280 ng/ml
HL in Microsomes > 60 min
Papp/Recovery = 8.4 (19)
WR308621
LogD = 2.1
HBDs = 3
Pf W2 IC90 = 46 ng/ml
Pf D6 IC90 = 92 ng/ml
PF C235 IC90 = 100 ng/ml
Pf C2A = 198 ng/ml
LC50 = 20300 ng/ml
HL in Microsomes > 60 min
Papp/Recovery <3 . 3( 2 8 )
WR318746
LogD = 2.0
HBDs = 3
Pf W2 IC90 = 90 ng/ml
Pf D6 IC90 = 155 ng/ml
PF C235 IC90 =283 ng/ml
Pf C2A = 319 ng/ml
LC50 = 28530 ng/ml
HL in Microsomes > 60 min
Papp/Recovery = 5.9 (42)
WR319535/581
LogD = 2.0
HBDs = 3
Pf W2 IC90 = 275 ng/ml
Pf D6 IC90 = 75 ng/ml
PF C235 IC90 =260 ng/ml
Pf C2A = 251 ng/ml
LC50 = 4110 ng/ml
HL in Microsomes > 60 min
Papp/Recovery =2 . 0( 5 2 )
Figure 3 Structures and key biological data for diamine quinoline methanols. The P. falciparum IC90 and RAW macrophage LC50 data for
mefloquine are presented as the mean +/- standard deviation. The LC50 values are against the macrophage cell line. Papp/recovery refers to
the apparent permeability in the apical direction across MDR1-transfected MDCK cell monolayers (units in 10
-6 cm/s) and the % recovery for
each compound at the end of the experiment.
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Page 7 of 10potent and exhibited improved selectivity indices relative
to mefloquine. In this study, it was observed that
WR177000 and related compounds such as WR308336
and WR308387 share a set of structural features essen-
tial for good potency; these are low molecular weight,
and unconjugated straight or branched-chain amines in
which the 4-position hydroxyl group is retained. The
library was structurally diverse within the constraints of
drug-like space. This suggests it may not be feasible to
synthesize quinoline methanols more potent than these
whilst retaining the physiochemical properties associated
with acceptable oral bioavailability.
As outlined previously and confirmed here, most qui-
noline methanols such as WR177000 and its analogs are
metabolically labile. They also exhibit greater permeabil-
ity than mefloquine across MDCK cell monolayers. In
general, metabolic lability can be resolved by lowering
lipophilicity [15]. Permeability across the blood-brain
barrier can be reduced by increasing MW, HBDs, HBAs,
PSA or lowering LogP or LogD. Ap r i o r i ,o n em i g h t
hypothesize that activity would be negatively affected by
the same trends, since impermeable compounds are also
likely to be inactive. Based on a global analysis of active
and inactive compounds, only LogP, LogD and HBDs
were not statistically associated with activity in the man-
ner one might suspect. These observations lead to the
hypothesis that within the constraints of drug-like space,
potency is more easily retainable when the scaffold is
modified to reduced blood-brain barrier permeability
through H-bond donor addition (as in WR308396),
rather than using the other strategies outlined above.
If so, diamine analogs of WR308396 would be
expected to be active, metabolically stable and exhibit
reduced permeability across MDCK cell monolayers. In
fact, they exhibited similar metabolic stability to meflo-
quine and lower permeability relative to mefloquine and
WR177000 analogs. All the diamines were active, albeit
with somewhat reduced potency relative to mefloquine.
Intriguingly, some of the cyclic diamines exhibited
altered cross-susceptibility profiles relative to meflo-
quine. Based on these observations, diamine analogs of
WR308396 appear to exhibit the best balance of desired
biological properties within the constraints of drug-like
space. A more detailed diamine SAR is currently being
developed through additional analog synthesis and char-
acterization in in vivo efficacy models and pharmacoki-
netic studies.
Conclusion
Mefloquine is one of the few available drugs that could
theoretically be used for malaria prophylaxis and IPT.
However, this potential may not be realized due to its
association with adverse CNS events at therapeutic
doses. An analog that did not cross the blood-brain
Table 4 Physiochemical properties of potent, active and inactive compounds
Parameter* Active Compounds with IC90s <
250 nM
Active Compounds with IC90s < 540 ng/ml
or 1000 nM
Inactive Compounds (IC90s > 540 ng/ml or
1000 nM)
Mean +/- STDEV (N) Mean +/- STDEV (N) Mean +/- STDEV (N)
MW 410 +/- 35 (25)**# 444 +/- 37 (66) 435 +/- 45 (107)
LogD 3.6 +/- 0.77 (24) 3.6 +/- 1.2 (66) 3.9 +/- 1.3 (106)
PSA 48 +/- 9.6 (25)** 57 +/- 18 (66)** 66 +/- 19 (106)
LogP 3.5 +/- 0.88 (25) 3.4 +/- 1.2 (66) 2.9 +/- 1.5 (106)
FRBs 6.3 +/- 1.7 (25) 6.5 +/- 1.7 (66)** 5.8 +/- 1.8 (106)
HBDs 1.8 +/- 0.55 (25) 1.8 +/- 0.8 (66) 2.0 +/- 0.98 (106)
HBAs 3.2 +/- 0.52 (25)**# 4.0 +/- 0.89 (66) 4.4 +/- 1.3 (106)
* MW is molecular weight, PSA = polar surface area, FRBs = freely rotatable bonds, HBDs = H-bond donors, HBAs = H bond acceptors and LVs = Lipinski
violations. Significant differences from inactive compounds or compounds with IC90s < 540 ng/ml/1000 nM# (one way ANOVA followed Bonferroni post-test, P <
0.05) are denoted by the symbols ** and # respectively.
Table 5 Proportions of different functional groups present in active and inactive amines
Chemical Property Number of Analogs in Subset of Active or Inactive Amines* P value**
Active (# of 69) (%) Inactive (# of 129) (%)
N or OH Replacement 1 (1.4) 12 (9.3) 0.036
Conjugated Amines 9 (13) 49 (38) 0.0003
Benzyl Amines 15 (22) 19 (15) 0.238
Side-chain Contains Heteroatoms 36 (52) 96 (74) 0.0025
Tertiary Amines 20 (29) 31 (24) 0.4964
Secondary Amines 49 (71) 78 (60) 0.0129
All Carbon Side-chain 21 (30) 8 (6.2) < 0.0001
* An active compounds is one with an IC90 < 1000 nM against PfC2A. ** Fisher’s exact, P < 0.05 considered significant.
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a library of drug-like, structurally diverse, non-piperidine
analogs of mefloquine was synthesized. From this library
an active series of diamines was identified with similar
metabolic stability and lower permeability than meflo-
quine. These compounds have one additional H-bond
donor compared to mefloquine. The in vivo efficacy and
pharmacokinetics of these compounds are currently
being investigated.
Additional file 1: Primary screening data and physiochemical
properties of next generation quinoline methanols. This EXCEL file
contains the structure number for 198 next generation quinoline
methanols together with their calculated physiochemical properties, IC90
values against four strains of P. falciparum, and LC50 values against RAW
macrophages. The compounds are broken out into three categories as
follows; potent compounds (IC90 < 250 nM), active compounds (IC90s
greater than 250 nM but less than either 1000 nM or 540 ng/ml) and
inactive compounds (IC90s > 1000 nM or 540 ng/ml). For each of these
three groups of compounds, the group means for each physiochemical
parameter are presented together with standard deviations and sample
size sizes. These data were used to perform the analyses outlined in
Table 4.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-2875-9-51-
S1.XLS]
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